1. Mylan, which has come under fire from lawmakers over significant price increases of its emergency allergy treatment EpiPen, said it will offer additional copay assistance to patients. The company plans to reduce out-of-pocket costs for the drug one day after presidential candidate Hillary Clinton said the drug’s price was “outrageous.” Mylan is not lowering the list price of the drug but will instead offer a savings card. (Reuters)

2. Mylan may have also violated antitrust law. Mylan’s EpiPen4Schools program — which offers free or discounted EpiPens to schools — at one point came with the stipulation that participating schools would not buy competitive products within the next 12 months. (Stat)

3. Digital and non-personal interaction between drugmakers and doctors has now exceeded the number of in-person visits made by sales reps, according to ZS Associates. The number of physicians open to in-person rep visits dropped to 44% in 2016 from 46% in 2015.

4. Teva Pharmaceutical Industries’ multiple sclerosis drug Copaxone had two of its patents invalided by the Patent Trial and Appeal Board. The company plans to appeal the ruling. (Bloomberg)

5. Novartis said a late-stage study demonstrated that its investigational oral multiple sclerosis drug, siponimod, reduced the risk of disability progression in a severe form of the disease. Data from the trial is expected to be presented next month at the European Committee for Treatment and Research in Multiple Sclerosis.